Food, Drugs, Healthcare, Life Sciences

The case of MedSleep Inc. v. The King (2025 TCC 70) deals with an important question under Canadian GST/HST law: when different parties work together to provide healthcare services, should those services be treated as one exempt medical service or as separate taxable business services?

On June 10, 2026, Québec adopted Bill 9, An Act to prevent the harmful effects of energy drinks on the health of young people (“Bill 9”), introducing a significant shift in how caffeinated energy drinks will be commercialized in the province. Bill 9 will come into force six months following assent, which is expected shortly.

Le 10 juin 2026, Québec a adopté le Projet de loi 9, Loi visant à prévenir les effets nocifs des boissons énergisantes sur la santé des jeunes (« Loi 9 »), qui introduit un changement important dans la façon dont les boissons énergisantes contenant de la caféine seront commercialisées dans la province. La Loi 9 entrera en vigueur six mois après la sanction, qui devrait être imminente.

Health Canada has announced a procedural shift that will eliminate the requirement to submit finished product specifications as part of Natural Health Product licence applications starting June 25, 2026.

The 2026 FIFA World Cup begins today. During the month-long tournament, BC is expected to welcome more than 350,000 enthusiastic and thirsty soccer fans from around the globe.

On June 10, 2026, Québec adopted Bill 9, An Act to prevent the harmful effects of energy drinks on the health of young people (“Bill 9”), introducing a significant shift in how caffeinated energy drinks will be commercialized in the province. Bill 9 will come into force six months following assent, which is expected shortly.

The 2026 annual Bloom Burton & Co. Healthcare Investor Conference—Canada's premier international forum for healthcare companies and investors—was held in late April in Toronto.

On March 26, 2026, Canada's new transfer pricing rules received royal assent and will have a significant impact on multi-national enterprises (MNEs) in life sciences industries.

Health Canada released a notice to industry on April 24, 2026, outlining that manufacturers must use the Regulatory Enrolment Process (REP) and Common Electronic Submission Gateway (CESG) for medical device transactions as of April 1, 2026. As we previously reported, manufacturers of medical devices could voluntarily use the REP and CESG for medical device regulatory transactions as of July 2024.